Aptamers to glycoprotein VI
The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of GPVI. The invention further relates to antidotes to GPVI aptamers and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention also relates to aptamers that bind to and enhance the activity of GPVI.
1. An aptamer that binds to and inhibits the activity of GPVI, wherein the aptamer comprises SEQ ID NO: 116.
2. A method of treating thrombosis in a human or non-human subject in need thereof comprising administering to said subject an amount of said aptamer according to claim 1 sufficient to effect said treatment.
3. The method according to claim 2 wherein said subject is undergoing percutaneous coronary intervention.
4. The method according to claim 2 wherein said subject suffers from an acute coronary syndrome.
5. A composition comprising the aptamer according to claim 1 and a carrier.
6. The aptamer of claim 1 , wherein the aptamer is selected from the group consisting of SEQ ID NO: 116, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 42 and SEQ ID NO: 45.
7. The aptamer of claim 6 , further comprising a carrier.
8. The aptamer of claim 1 , further comprising a modified nucleotide.
9. The aptamer of claim 8 , wherein the modified nucleotide is a 2′ O-methyl nucleotide.
10. The aptamer of claim 6 , further comprising a modified nucleotide.
11. The aptamer of claim 10 , wherein the modified nucleotide is a 2′ O-methyl nucleotide.
12. A method of inhibiting platelet aggregation in a human or non-human subject in need thereof comprising administering to said subject an amount of said aptamer according to claim 1 sufficient to effect said treatment.
13. A method of treating thrombosis in a human or non-human subject in need thereof comprising administering to said subject an amount of said aptamer according to claim 6 sufficient to effect said treatment.
14. The method according to claim 13 wherein said subject is undergoing percutaneous coronary intervention.
15. The method according to claim 13 wherein said subject suffers from an acute coronary syndrome.
16. A method of inhibiting platelet aggregation in a human or non-human subject in need thereof comprising administering to said subject an amount of said aptamer according to claim 6 sufficient to effect said treatment.